R&D Progress: NMPA Approves Genakumab to the Market

April 11th, 2024, Shanghai - Changchun GeneScience Pharmaceuticals Co., Ltd. (GenSci) received the "Acceptance Notice" from the National Medical Products Administration (NMPA), signaling the acceptance of their marketing application for GenSci's Genakumab. This development is auspicious, as Genakumab's indication for acute gouty arthritis has been recognized. It's a significant step forward, indicating progress towards addressing the medical needs of those suffering from this condition. Relevant research suggests that an overabundance of interleukin (IL) is a pathogenic factor in various inflammatory diseases. Anti-IL-1β antibodies can rapidly and specifically block the binding of IL-1β to its receptor, thereby inhibiting inflammation. The company's Genakumab is a Category 1 new biological product intended for therapeutic use. It is produced using genetic engineering techniques and other methods, and it serves as an anti-IL-1β antibody medication. Additionally, Genakumab is currently in the clinical research phase for indications such as systemic juvenile idiopathic arthritis and interstitial lung disease. Previous: Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024 Next: GenSci Launches Global Innovation Hub in Shanghai Recommended News 2026-09-03 GenSci Showcases Innovation at CPHI Korea 2026 2026-08-13 GenSci's Ophthalmology Pipeline: IND Approval Secured for Three Indications 2026-07-31 GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPA

The release as fetched from its publisher. genscigroup.com ↗